Dr. Reddy’s Laboratories has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of Valcyte (Valganciclovir) tablets in the US market on December 15, 2014, approved by the United States Food & Drug Administration (USFDA). The company’s Valganciclovir tablets, USP in 450 mg is available in bottle counts of 60.
The Valcyte (Valganciclovir) tablets brand had U.S. sales of around $440 million MAT for the most recent twelve months ending in October 2014, according to IMS Health.
Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1532.85 |
Dr. Reddys Lab | 5812.50 |
Cipla | 1403.90 |
Zydus Lifesciences | 1104.45 |
Lupin | 1661.90 |
View more.. |